title: Cytomegalovirus Pneumonia in Patients with Rheumatic Diseases After Immunosuppressive Therapy: A Single Center Study in China.
abstract: BACKGROUND
  Rheumatic diseases involve multiple organs that are affected by immunological mechanisms. Treatment with corticosteroids and immunosuppressive agents may also increase the frequency of infection. Cytomegalovirus (CMV) is a widespread herpes virus and a well-recognized pathogen, which causes an opportunistic and potentially fatal infection in immunocompromised patients. This retrospective study aimed to investigate the clinical and laboratory characteristics of CMV pneumonia in patients with rheumatic diseases after immunosuppressive therapy in a single center in Shanghai, China.
  
  
  METHODS
  Eight hundred and thirty-four patients with rheumatic diseases who had undergone CMV-DNA viral load tests were included, and the medical records of 142 patients who were positive for CMV-DNA in plasma samples were evaluated. GraphPad Prism version 5.013 (San Diego, CA, USA) was used to conduct statistical analysis. The correlation between CMV-DNA viral loads and lymphocyte counts was assessed using the Spearman rank correlation coefficient test. Significance between qualitative data was analyzed using Pearson's Chi-squared test. The cut-off thresholds for CMV-DNA viral load and lymphocyte count were determined by receiver operating characteristic (ROC) curve analysis.
  
  
  RESULTS
  One hundred and forty-two patients had positive CMV viral load tests. Of these 142 patients, 73 patients with CMV pneumonia were regarded as symptomatic, and the other 69 were asymptomatic. The symptomatic group received higher doses of prednisolone (PSL) and more frequently immunosuppressants than the asymptomatic group (P < 0.01). The symptomatic group had lower lymphocyte counts, especially CD4+ T-cells, than the asymptomatic group (P < 0.01). By ROC curve analysis, when CD4+ T-cell count was <0.39 × 109/L, patients with rheumatic diseases were at high risk for symptomatic CMV infection. The CMV-DNA load was significantly higher in the symptomatic patients than that in asymptomatic patients (P < 0.01; threshold viral loads: 1.75 × 104 copies/ml). Seven patients had a fatal outcome, and they had lower peripheral lymphocyte counts (P < 0.01), including CD4+ and CD8+ T-cells (P < 0.01).
  
  
  CONCLUSIONS
  When CD4+ T-cell count is <0.39 × 109/L, patients are at high risk for pulmonary CMV infection. Patients are prone to be symptomatic with CMV-DNA load >1.75 × 104 copies/ml. Lymphopenia (especially CD4+ T-cells), presence of symptoms, and other infections, especially fungal infection, are significant risk factors for poor outcome, and a higher PSL dosage combined with immunosuppressants may predict CMV pneumonia.
authors.forename: Yu
authors.initials: Y
authors.lastname: Xue
authors.forename: Li
authors.initials: L
authors.lastname: Jiang
authors.forename: Wei-Guo
authors.initials: WG
authors.lastname: Wan
authors.forename: Yu-Ming
authors.initials: YM
authors.lastname: Chen
authors.forename: Jiong
authors.initials: J
authors.lastname: Zhang
authors.affiliation: Institute of Rheumatology, Immunology and Allergy, Fudan University, Shanghai 200040; Department of Rheumatology, Linyi People's Hospital, Linyi, Shandong 276000, China.
authors.forename: Zhen-Chun
authors.initials: ZC
authors.lastname: Zhang
mesh_terms: D015496:CD4-Positive T-Lymphocytes / Q000378:metabolism; D002681:China; D003587:Cytomegalovirus / Q000472:pathogenicity*; D003586:Cytomegalovirus Infections / Q000235:genetics / Q000276:immunology / Q000628:therapy* / Q000821:virology*; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods*; D011014:Pneumonia / Q000235:genetics / Q000276:immunology / Q000628:therapy* / Q000821:virology*; D016133:Polymerase Chain Reaction; D012189:Retrospective Studies; D012216:Rheumatic Diseases / Q000235:genetics / Q000276:immunology / Q000628:therapy* / Q000821:virology*; D019562:Viral Load
references.citation: Chin Med J (Engl). 2001 Dec;114(12):1309-12
references.pmid: 11793860
references.citation: J Rheumatol. 2000 Nov;27(11):2715-7
references.pmid: 11093460
references.citation: Clin Exp Rheumatol. 2002 Jul-Aug;20(4):559-64
references.pmid: 12175116
references.citation: J Am Soc Nephrol. 2002 Oct;13(10):2577-84
references.pmid: 12239248
references.citation: Immunogenetics. 2002 Nov;54(8):527-42
references.pmid: 12439615
references.citation: Mayo Clin Proc. 2003 Nov;78(11):1412-5
references.pmid: 14601702
references.citation: J Rheumatol. 2004 Jul;31(7):1349-51
references.pmid: 15229955
references.citation: Clin Exp Rheumatol. 2004 Jan-Feb;22(3 Suppl 33):S31-4
references.pmid: 15344595
references.citation: J Med Microbiol. 2004 Nov;53(Pt 11):1155-60
references.pmid: 15496396
references.citation: Arthritis Rheum. 1974 Jan-Feb;17(1):1-10
references.pmid: 4810662
references.citation: Bull World Health Organ. 1973;49(1):103-6
references.pmid: 4363395
references.citation: J Rheumatol. 1989 May;16(5):677-80
references.pmid: 2547061
references.citation: Blood. 1992 Sep 1;80(5):1358-64
references.pmid: 1325214
references.citation: J Rheumatol. 1993 Jan;20(1):155-7
references.pmid: 8382745
references.citation: Arthritis Rheum. 1995 Feb;38(2):291-2
references.pmid: 7848322
references.citation: Retina. 1995;15(2):169-70
references.pmid: 7624608
references.citation: J Rheumatol. 1995 Jul;22(7):1254-8
references.pmid: 7562754
references.citation: Ann Rheum Dis. 1995 Dec;54(12):991-4
references.pmid: 8546533
references.citation: J Clin Microbiol. 1996 Feb;34(2):457-9
references.pmid: 8789039
references.citation: Arthritis Rheum. 1996 Sep;39(9):1475-82
references.pmid: 8814058
references.citation: J Rheumatol. 1996 Jul;23(7):1186-8
references.pmid: 8823690
references.citation: Blood. 1996 Nov 15;88(10):4063-71
references.pmid: 8916975
references.citation: Semin Arthritis Rheum. 1996 Dec;26(3):635-40
references.pmid: 8989808
references.citation: Arthritis Rheum. 1998 Mar;41(3):414-20
references.pmid: 9506568
references.citation: Am J Transplant. 2005 Jan;5(1):110-7
references.pmid: 15636618
references.citation: Am J Transplant. 2005 Feb;5(2):218-27
references.pmid: 15643981
references.citation: Mod Rheumatol. 2006;16(3):137-42
references.pmid: 16767551
references.citation: J Infect Dis. 2007 Nov 1;196(9):1288-95
references.pmid: 17922392
references.citation: Rheumatology (Oxford). 2008 Sep;47(9):1373-8
references.pmid: 18577548
references.citation: Autoimmun Rev. 2008 Dec;8(2):89-91
references.pmid: 18725325
references.citation: Arthritis Res Ther. 2009;11(1):R27
references.pmid: 19232124
references.citation: J Leukoc Biol. 2010 Mar;87(3):385-95
references.pmid: 20015961
references.citation: Ann Rheum Dis. 2011 May;70(5):785-91
references.pmid: 21288960
references.citation: Virus Res. 2011 May;157(2):151-60
references.pmid: 21056604
references.citation: J Clin Microbiol. 2000 Jul;38(7):2536-42
references.pmid: 10878039
references.citation: Intern Med. 2002 Feb;41(2):151-5
references.pmid: 11868605